Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Itri, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Itri, L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 2289-2293
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy

Loretta M. Itri

Genta, Inc., Berkeley Heights, New Jersey, USA

Keywords: anaemia; epoetin alfa

Introduction

Epoetin alfa has been used effectively for over a decade as hormone replacement therapy in the treatment of anaemia in patients with chronic renal failure (chronic kidney disease). In this condition, erythropoietin production is impaired and the resulting deficiency is the primary cause of the normocytic, normochromic anaemia typically observed [1]. The recommended initial epoetin alfa dosages in this patient population are 50–100 U/kg three times weekly (TIW) intravenously (i.v.) or subcutaneously (s.c.) in adults and 50 U/kg TIW i.v. or s.c. in children. Because of the extensive experience with epoetin alfa in the nephrology community, oncologists may seek advice in the use of the drug to treat cancer-related anaemia. It is important to note that the pathogenesis of cancer-related anaemia differs from that of the anaemia of chronic renal failure. While the aetiology of anaemia in patients with cancer can be multifactorial, it closely resembles the anaemia . . . [Full Text of this Article]

Cancer-related anaemia and its impact

Epoetin alfa and cancer-related anaemia

Once-weekly epoetin alfa dosing

Summary

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?